Analyst Ratings for [SGMT] Sagimet Biosciences Inc.

7/24/25	Initiated	Buy	X
SGMT Sagimet Biosciences Canaccord Genuity
$28
12/6/24	Initiated	Outperform	X
SGMT Sagimet Biosciences Oppenheimer
$30
11/12/24	Initiated	Buy	X
SGMT Sagimet Biosciences UBS
$12
6/28/24	Downgrades	Buy Neutral	X
SGMT Sagimet Biosciences Goldman
$23 $6
5/2/24	Initiated	Buy	X
SGMT Sagimet Biosciences H.C. Wainwright
$32
3/25/24	Initiated	Outperform	X
SGMT Sagimet Biosciences Leerink Partners
$26
8/8/23	Initiated	Buy	X
SGMT Sagimet Biosciences Goldman
$33
8/8/23	Initiated	Mkt Outperform	X
SGMT Sagimet Biosciences JMP Securities
$30
8/8/23	Initiated	Overweight	X
SGMT Sagimet Biosciences Piper Sandler
$67
8/8/23	Initiated	Outperform	X
SGMT Sagimet Biosciences TD Cowen

SGMT Sagimet Biosciences Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.